Otros idiomas Ionis Pharmaceuticals, Inc.

Acciones

IONS

US4622221004

Biotecnología e investigación médica

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 20/01/2026			Variación 5 días	Varia. 1 de enero.
77,53 ^USD	+1,57 %		-2,45 %	-2,00 %

13/01	Ionis Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 08:15 AM
12/01	Ionis Pharmaceuticals, Inc. presenta actualizaciones adicionales sobre hitos clave previstos para 2026	CI

Otros idiomas

12/01	Ionis Pharmaceuticals, Inc. Provides Additional Updates on Key Milestones Expected in 2026
12/01	Biogen says co received European Commission approval for high dose regimen of Spinraza
12/01	Ionis Pharmaceuticals : 2026 Ionis JPMorgan Presentation
12/01	Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
09/01	Ionis Pharmaceuticals Insider Sold Shares Worth $3,760,577, According to a Recent SEC Filing
07/01	European Stocks Close Mixed in Wednesday Trading; Euro Area Inflation Declines in December
07/01	GSK plc Announces Positive Topline Results from B-Well 1 and B-Well 2 Phase 3 Studies for Bepirovirsen
07/01	GSK Reports 'Positive' Phase 3 Results From Chronic Hepatitis B Studies
07/01	Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
06/01	Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
07/12	Ionis Pharmaceuticals : 2025 12 ASH Palmer Sapablursen PV IMPRSSION Slides
06/12	Deciphera Pharmaceuticals Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemiaera at the 67th American Society of Hematology Annual Meeting
02/12	Ionis Pharmaceuticals, Inc. Receives U.S. Fda Breakthrough Therapy Designation for Zilganersen for Alexander Disease
02/12	Sector Update: Health Care Stocks Mixed Premarket Tuesday
02/12	Ionis Pharmaceuticals' Investigational Alexander Disease Treatment Granted Breakthrough Therapy Designation
02/12	Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
01/12	Ionis Pharmaceuticals, Inc. Receives U.S. Fda Breakthrough Therapy Designation for Olezarsen for Severe Hypertriglyceridemia
01/12	Ionis receives U.S. FDA breakthrough therapy designation for olezarsen for severe hypertriglyceridemia
01/12	Ionis Says Olezarsen Gets FDA Breakthrough Therapy Designation for Severe Hypertriglyceridemia
01/12	Ionis Pharmaceuticals shares up 3.5% premarket after co receives FDA breakthrough therapy designation for olezarsen for SHTG
01/12	Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
01/12	Ionis Pharmaceuticals Insider Sold Shares Worth $1,357,442, According to a Recent SEC Filing
24/11	Praxis Precision Medicines, Inc. to Present Latest Preclinical and Clinical Advancements Across Leading Epilepsy Portfolio at the 2025 American Epilepsy Society Annual Meeting
19/11	Arrowhead Pharmaceuticals Poised for Commercial Transition After First FDA Approval, RBC Says
18/11	US FDA approves Arrowhead's genetic disorder drug

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripciones Comunicados Publs. oficiales Otros idiomas Artículos de MarketScreener Estrategias MarketScreener Ideas de trading

Otros idiomas Ionis Pharmaceuticals, Inc.

Acciones

IONS

US4622221004

Biotecnología e investigación médica

Otros idiomas

Filtros